Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of TK006 in Post-menopausal Women
NCT03242512Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Aug 2017
- Primary completion
- Dec 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of TK006 in osteoporosis (3 cohorts), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Incidence of adverse events up to 252 days. Status: unknown.
02
Drugs
TK006
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03242512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03242512.